School of Medicine


Showing 311-320 of 630 Results

  • Mark Krasnow

    Mark Krasnow

    Paul and Mildred Berg Professor

    Current Research and Scholarly Interests- Lung development and stem cells
    - Neural circuits of breathing and speaking
    - Lung diseases including lung cancer
    - New genetic model organism for biology, behavior, health and conservation

  • Anandi Krishnan

    Anandi Krishnan

    Affiliate, Institute for Immunity, Transplantation, and Infection Operations
    Visiting Scholar, Institute for Immunity, Transplantation, and Infection Operations

    BioDr. Krishnan is a translational scientist with experiences in engineering, biosciences, molecular genetics and hematology. As a current NIH mentored career development awardee (NHGRI 1K08HG010061-01A1), and recent NIH-supported research re-entry (NCATS 3UL1TR001085-04S1), Anandi’s interests are in expanding our understanding of the multifaceted function of anucleate blood platelets and their parent megakaryocytes in human disease.

    Her current work, applying platelet transcriptome profiling and machine learning principles, aims to nominate novel clinically relevant strategies for personalized cancer and antiplatelet/antithrombotic therapy. Continued development of this research is likely to identify key mechanistic variables in platelet- and megakaryocyte-specific response to health and disease.

    Recent contributions in both computational and mechanistic components of platelet and blood research lay the groundwork for sustaining contributions to the field of hematology genomic medicine (e.g. Shen et al PMID 34755136, Seetharam et al PMID 36712071, Kelliher et al PMID 37961700, Thomas & Krishnan PMID 38175681, Abbonante et al PMID 38165147, Jutzi et al PMID 35763665, Campbell et al PMID 36194487). Anandi was also was one of the first non-MD PhD scientist to be awarded the NHGRI K08 Clinical Scientist Research Career Development Award, the HTRS Mid-Career Research Award, and the MPN Research Foundation Challenge Grant Award, reflecting her consistent efforts bridging basic and clinical disciplines.

    Select other recognitions include:
    Member, Editorial Board, Journal of Thrombosis and Haemostasis (2024-)
    Ad hoc Reviewer, NIH CSR Cancer and Hematological Disorders Study Section (2023, 24)
    Host Mentor, ISTH Training Fellowship, International Society for Thrombosis and Haemostasis (2023)
    Member, Minority Recruitment Initiatives Subcommittee, American Society of Hematology (2022-26)
    Team Science Leadership Program at Stanford Medicine (2022)
    Peer Mentor, Pathology Stanford Network for Advancement and Promotion (2021)
    Research Mentor, Meharry Medical College, Nashville, Meharry-Stanford initiative *mentee selected for oral presentation & won 2nd place at Meharry (2021)
    Thrombosis & Hemostasis Societies of North America Young Investigator Award (2020)
    Invited Member and Panelist, NSF RESET Conference (2020)
    Invited Member/Panelist, iRelaunch Return to Work Conference, Stanford Alumni Association (2018)
    Featured twice by NIH NCATS in the ‘Features & Briefs’ & ‘Diversity Awardee Profiles’ webpages (2017,18)

    Complete list of publications: https://pubmed.ncbi.nlm.nih.gov/?term=anandi+krishnan&sort_order=asc

  • Calvin Kuo

    Calvin Kuo

    Maureen Lyles D'Ambrogio Professor

    Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.

  • Allison W. Kurian, M.D., M.Sc.

    Allison W. Kurian, M.D., M.Sc.

    Professor of Medicine (Oncology) and of Epidemiology and Population Health

    Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.

  • David Kurtz

    David Kurtz

    Assistant Professor of Medicine (Oncology)
    On Partial Leave from 05/01/2024 To 04/30/2025

    Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.

  • Bernice Kwong, MD

    Bernice Kwong, MD

    Clinical Professor, Dermatology

    BioBernice Kwong, M.D., is Clinical Professor of Dermatology, Director of the Supportive Dermato-Oncology Program, and Director of the Inpatient Dermatology Consult Service. She has a special interest in the management of cutaneous complications that arise in hospitalized patients and cancer patients. She runs the Supportive Dermato-Oncology Program at the Stanford Cancer Center, where she manages skin side effects of cancer therapies including chemotherapy-related skin reactions, radiation dermatitis, and graft-versus-host disease. Dr. Kwong completed medical school at Yale University, and completed her dermatology residency at Stanford University in 2012.

  • Norman J. Lacayo, MD

    Norman J. Lacayo, MD

    Associate Professor of Pediatrics (Hematology and Oncology)

    Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.